The company now expects the health benefits ratio for the full year to be in the range of 88.9% to 89.5%, up from its previous guidance of 88.4% to 89%.
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.
Retail investors are raising concerns over U.S. Treasury Secretary Scott Bessent's recent remarks on tariffs and the ongoing trade tensions with China, delivered at a closed-door investor summit hosted by JPMorgan Chase & Co. (NYSE: JPM).
Chipotle said Trump’s tariffs might raise its cost of sales by about 0.5% this year, which could translate to tens of millions of dollars in extra spending.
Samantha Harris, Tesla's Global Sustainability Lead, was scheduled to speak at the Regenerative Future conference, planned for May 16-17 in Rome by the European Institute of Innovation and Sustainability (EIIS).
The company now expects 2025 revenue to be in the range of $43.3 billion to $44.2 billion and adjusted EPS to be in the range of $21.76 to $22.84, compared with its previous forecast of $23.10 to $23.50.
Many investors start their journey by buying stocks they like, chasing dividends, or diversifying across various assets, only to later realize their portfolio needs a serious overhaul.
